



**ST. JOSEPH HOSPITAL
LABORATORY SERVICES**

360 Broadway
Bangor, ME 04401

**ANTIBIOGRAM
ANTIBIOTIC SUSCEPTIBILITY OF COMMON ORGANISMS**

Percent Susceptible – 2025 (Jan – Dec)

GRAM NEGATIVE ORGANISMS	No. of Isolates	Ampicillin	Amoxicillin- Clavulanate	Amp /Sulbactam (Unasyn)	Cefazolin	Cefepime	Ceftazidime (Fortaz)	Ceftriaxone	Ciprofloxacin	Gentamicin	Levofloxacin	Meropenem	Nitrofurantoin (urinary isolates)	Pip / Tazo (Zosyn)	Tobramycin	Trimeth / Sulta (Bactrim)
Citrobacter freundii*	48	0	0	0	2	100	92	79	100	96	98	100	100	100	97	94
Enterobacter cloacae	44	0	0	0	2	95	75	66	98	100	98	100	26	84	100	86
Escherichia coli- Urinary	1090	66	92	72	93	97	96	95	84	92	86	100	98	100	93	83
Escherichia coli- Systemic	67	57	94	64	73	91	90	90	78	87	85	100	-	97	88	78
Klebsiella aerogenes	24	0	0	0	12	96	71	67	96	100	100	100	21	92	100	100
Klebsiella oxytoca	58	0	91	79	74	100	100	91	98	100	100	100	92	93	100	100
Klebsiella pneumoniae	236	0	94	85	89	94	92	90	85	99	93	100	58	100	97	86
Proteus mirabilis	77	96	97	99	99	100	100	100	92	99	92	100	0	100	99	91
Pseudomonas aeruginosa	80	-	-	-	-	94	89	-	90	94	85	100	-	92	100	-
Serratia marcescens*	25	0	0	0	0	100	60	60	88	100	92	100	0	80	100	100

Haemophilus influenza	# Of Isolates= 3	Beta-lactamase positive= 33.3%
E. coli ESBL (Extended-spectrum beta-lactamase)	Isolated in 5% of all Escherichia coli tested.	

Other antimicrobials that are tested but not reported are available by calling the Microbiology Laboratory at ext. 1653

*Calculated from 2024 & 2025 data.



**ST. JOSEPH HOSPITAL
LABORATORY SERVICES**

360 Broadway
Bangor, ME 04401

**ANTIBIOGRAM
ANTIBIOTIC SUSCEPTIBILITY OF COMMON ORGANISMS**

Percent Susceptible –2025 (Jan – Dec)

GRAM POSITIVE ORGANISMS	No. of Isolates	Ampicillin	Ampicillin/ Sulbactam	Amoxicillin/ Clavulanate	Ciprofloxacin	Clindamycin	Daptomycin	Erythromycin	Gentamicin- for synergy only, not monotherapy	Levofloxacin	Linezolid	Oxacillin	Tetracycline	Trimeth / Sulfa (Bactrim)	Vancomycin
Staph aureus (MSSA)	177	0	100	100	88	78	100	60	99	89	100	100	91	100	100
Staph aureus (MRSA)	134	0	0	0	46	54	97	6	95	46	99	0	84	95	100
Staph epidermidis	52	0	29	29	83	73	100	40	96	83	100	33	71	55	100
Enterococcus faecalis	110	100	-	-	77	-	100	22	-	81	97	-	28	-	92
Enterococcus faecium*	11	45	-	-	27	-	82	0	-	27	100	-	55	-	64

Streptococcus pneumoniae (NOTE: Penicillin results are based on PO therapy for non-meningitis)	No. of isolates 18	<u>Beta Lactamase</u> Sensitive= 94% Intermediate = 6% Resistant = 0%
MRSA (Methicillin Resistant Staph Aureus)	Isolated in 43% of all Staph aureus tested	
VRE (Vancomycin Resistant Enterococcus)	E. faecalis: 8% resistant to Vancomycin E. faecium*: 27% resistant to Vancomycin	

46

Analytic method used – % susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

^: **MSSA, by definition, is susceptible to Oxacillin and Ceftriaxone.**

Reference: Performance Standards for Antimicrobial Testing. CLSI M100S-February 2024

*Calculated from 2024 & 2025 data.